• LinkedIn
  • Facebook
  • Instagram
  • Twitter
  • Five_100_px
 
Anuncia
  • (978) 942-5600
  • [email protected]
  • Home
  • ABOUT
    • The Anuncia Story
    • Meet the Team
  • RESOURCES
    • News & Blogs
    • Professional Associations
  • For Patients
    • What is Hydrocephalus?
    • Our ReFlow™ Technology
    • Patient Stories
    • Frequently Asked Questions
  • For Clinicians
    • Product Information
  • Investor Relations
  • Careers
  • Contact
  • Menu Menu

Alcyone Lifesciences Completes Spin-Off of Hydrocephalus Business, Anuncia

February 20, 2018

Alcyone Lifesciences, Inc., announces the separation and spin-off of its Hydrocephalus business. The new company, known as Anuncia, Inc., is an independent company focused on innovative treatment of Hydrocephalus and cerebrospinal fluid dysfunctions.

LOWELL, Mass., Feb. 20, 2018 /PRNewswire/ — Alcyone Lifesciences, Inc., a privately-held company focused on transforming disease modifying therapies for central nervous system (CNS) disorders today announced the separation and spin-off of its Hydrocephalus business. The new company, known as Anuncia, Inc., is an independent company focused on innovative treatment of Hydrocephalus and cerebrospinal fluid dysfunctions.

The separation and spin-off of Anuncia from Alcyone comes on the heels of receiving the EU CE Mark and US FDA Clearance of ReFlow Ventricular System for the treatment of hydrocephalus. The FDA 510(k) clearance and EU approval of the ReFlow Ventricular System permits Anuncia to commercialize the innovative technology for treatment of hydrocephalus in the US, and Europe, to provide qualified clinicians with the option of non-invasive retrograde flushing of the ventricular catheter, to unblock occluded inlet holes or open a relief membrane to restore or increase cerebrospinal fluid (CSF) flow in a non-flowing shunt.

Hydrocephalus is a condition in which an excess of CSF accumulates within the ventricles and increases pressure in the brain, resulting in a life-threatening situation. CSF shunts are implantable devices inserted by neurosurgeons to treat Hydrocephalus. Although shunts facilitate treatment for many cases, according to The Hydrocephalus Association1 at least 50 percent of patients implanted with shunts suffer from shunt failures and blockages within two years, requiring repeated revision surgeries. Further, according to Sarkiss et al., 2014, 40 percent of obstructions, the leading cause of shunt failure, have been shown to occur within the first-year post surgery.

The costs of these, often-emergent, revision surgeries to restore CSF flow and alleviate painful symptoms, present a heavy emotional and financial burden to patients, families, and healthcare facilities. Though the Alivio Flusher is not intended to change standard care practices for diagnosis, treatment, or follow-up of patients with proximal catheter occlusions; it is designed to provide a non-invasive option for neurosurgeons to restore CSF flow in a non-flowing shunt, which may potentially avert emergency revision surgery.

“Alcyone Lifesciences and Anuncia will each be stronger, more focused and more competitive as leading standalone companies in their respective markets,” said Edgar D. Jannotta, Jr., Director at Alcyone and Anuncia. “This decision comes after a thorough strategic review by the Board that showed that as independent companies, Alcyone and Anuncia, will be better positioned competitively and enjoy added flexibility to pursue strategic partnerships in their respective markets.”

Jeffrey Quillen and Patrick Connolly of Foley Hoag LLP advised Alcyone in connection with the spin-off and will represent Alcyone and Anuncia as general corporate counsel going forward.

Alcyone Lifesciences, Inc.
Alcyone Lifesciences, based in Massachusetts, is a privately-held company focused on transforming disease modifying therapies for rare, orphan and debilitating neurological disorders through an advanced precision delivery platform. For more information, please visit www.alcyonels.com

Anuncia, Inc.
Anuncia, based in Massachusetts, is an independent privately-held company focused on developing products for better treatment of hydrocephalus and CSF dysfunctions. For more information please visit www.reflowventcath.com

https://anunciamedical.com/wp-content/uploads/2023/08/Blog-Post-Logo.png 430 760 admin https://anunciamedical.com/wp-content/uploads/2023/12/LowResPNG__Anuncia-Stacked_COLOR_.png admin2018-02-20 02:51:412023-12-12 14:23:34Alcyone Lifesciences Completes Spin-Off of Hydrocephalus Business, Anuncia

Pages

  • Careers
  • Contact
  • Cookie Policy
  • FAQs
  • For Clinicians
  • Home
  • Investor Relations
  • News & Blogs
  • Our Technology
  • Patient Stories
  • Privacy Policy
  • Professional Associations
  • Publications
  • Thank You!
  • The Anuncia Story
  • What is Hydrocephalus?

Categories

  • Anuncia News
  • Educational Information
  • Press Releases
  • Uncategorized

Archive

  • March 2025
  • June 2024
  • December 2023
  • August 2023
  • July 2023
  • May 2023
  • October 2022
  • March 2022
  • February 2022
  • July 2021
  • June 2021
  • May 2021
  • March 2021
  • May 2019
  • December 2018
  • May 2018
  • February 2018

Contact your physician to discuss if the ReFlow™ System Mini may be right for you.

Additional information about the ReFlow™ System Mini is available by contacting Anuncia.

(978) 942-5600 | [email protected]

Our Address

6908 E Thomas Road
Suite 302
Scottsdale, AZ 85251

Directions

Disclaimer

The ReFlow™ System Mini and ReFlow Mini Flusher are FDA cleared for use in the treatment of patients with hydrocephalus or conditions where draining or shunting of cerebrospinal fluid (CSF) is medically indicated. The ReFlow™ System Mini and ReFlow™ Mini Flusher are not for everyone; please consult your doctor. The ReFlow™ System Mini and ReFlow™ Mini Flusher are only available in the United States. The ReFlow™ System Mini and ReFlow™ Mini Flusher are prescription devices sold by or on the order of a physician.

Caution: FDA (USA) law restricts this device to sale by or on the order of a physician. Refer to product package insert for instructions, warnings, precautions and complications.

Medical Advice Disclaimer

Information on this site is for informational purposes only and should not be used as a substitute for talking with your doctor. No representation is made that the information provided is current, complete, or accurate. Always consult with your doctor about your medical questions, health, diagnosis, and treatment information.

Trademark Legal Notice

All logos, and brands are property of their respective owners in the United States and/or other countries. All company, product and service names used on this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement.

Anuncia Inc. is not affiliated with or an official partner of MD&DI, Fast Company, and The FDA.

© 2024 Anuncia Inc. All Rights Reserved. Website by Honeywick   |   Privacy Policy   |   Cookie Policy
Scroll to top

Contact Us